Immunopharmacological study of CCA (Lobenzarit disodium), an anti-arthritis agent--I. Abrogation of IL 1 secretion by LPS-stimulated human monocytes and induction of gamma-interferon production with CCA.
In vitro effects of CCA, an anti-arthritis agent, were studied upon autologous mixed lymphocyte reaction (AMLR), lymphocyte mitogenesis, IL 1 and IL 2 production, immunoglobulin production and gamma-interferon (IFN) production. CCA at 50 micrograms/ml, which was not toxic to cells, blocked AMLR, IL 1 production and immunoglobulin production (IgM and IgG) significantly, while CCA at the same dose did not affect IL 2 production and lymphocyte mitogenic responses to Staphylococcus aureus Cowan I(SAC) and pokeweed mitogen(PWM). CCA at both 20 ng/ml and 20 micrograms/ml induced human gamma/IFN. Addition of IL 1 and/or IL 2 reversed inhibitory effect of CCA on AMLR. These data suggest that CCA exerts its actions by mainly affecting T cells and monocytes and can be used as an immunomodulator.
D006801:Humans; D007369:Interferon Inducers; D007371:Interferon-gamma / Q000096:biosynthesis*; D007375:Interleukin-1 / Q000096:biosynthesis* / Q000276:immunology; D007376:Interleukin-2 / Q000276:immunology; D008070:Lipopolysaccharides; D008213:Lymphocyte Activation / Q000187:drug effects*; D008214:Lymphocytes / Q000187:drug effects* / Q000276:immunology; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D062367:ortho-Aminobenzoates / Q000494:pharmacology*
D007369:Interferon Inducers; D007375:Interleukin-1; D007376:Interleukin-2; D008070:Lipopolysaccharides; D062367:ortho-Aminobenzoates; D007371:Interferon-gamma; C015735:lobenzarit